Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Increase of Options from 10% to 14% of outstanding Shares

<< Previous

Bullboard Posts

Next >>

Comment by Probosciseson Apr 07, 2023 12:00am

142 Views

Post# 35384334

RE:RE:RE:RE:RE:Increase of Options from 10% to 14% of outstanding Shares

Noteable, you have jumped to the wrong conclusion re. inthno. I have known him from my own attendance at Calgary AGMs since the early 2000s. I probably met inthno at 3 or 4 Calgary AGMs, the last one being in 2013.

Like inthno I also have not recieved my AGM package in the mail though I have most other years. I will try to get that straightened out tomorrow.

<< Previous

Bullboard Posts

Next >>

Dollar Tree CEO Rick Dreiling steps down as discount retailer struggles